TGF-beta Signalling in Cancer: Suppressor Early, Promoter Late

The Core Pathway

TGF-beta ligands bind a type II receptor that recruits and phosphorylates a type I receptor. The activated receptor phosphorylates the receptor-regulated SMAD proteins (SMAD2 and SMAD3), which partner with SMAD4 and move to the nucleus to regulate transcription.

There is also SMAD-independent signalling through MAPK, PI3K and Rho pathways, which becomes more prominent in the pro-tumour phase.

The Tumour-Suppressor Phase

In normal epithelium, TGF-beta induces the CDK inhibitors p15 and p21 and represses MYC, producing a G1 arrest. It also promotes differentiation and apoptosis in the right context.

Early tumours often disable this arm: pancreatic and colorectal cancers frequently delete or mutate SMAD4, and other tumours mutate the receptors, removing the growth-inhibitory response while leaving other pathway outputs intact.

The Tumour-Promoting Phase

Once cells are freed from growth inhibition, TGF-beta in the tumour microenvironment drives epithelial-mesenchymal transition, increasing motility and invasiveness. It stimulates cancer-associated fibroblasts, promotes angiogenesis and remodels the extracellular matrix.

It is also strongly immunosuppressive, excluding cytotoxic T cells from tumours and dampening their function, which is thought to contribute to resistance to immune-checkpoint inhibitors.

Therapeutic Implications

Because blanket TGF-beta inhibition could remove a tumour suppressor and cause cardiac and other toxicity, development has focused on the pro-tumour, microenvironmental phase, particularly combinations with immunotherapy.

Approaches include ligand traps, receptor kinase inhibitors and bifunctional molecules that combine TGF-beta blockade with PD-L1 blockade. Results so far are mixed.

Interpretation Notes

A SMAD4 loss finding indicates disruption of the growth-inhibitory arm and, in pancreatic and colorectal cancer, is associated with more aggressive behaviour in some series.

TGF-beta pathway activity signatures are used in research to predict immunotherapy resistance but are not standard clinical tests.

Key Takeaways

• ·TGF-beta signals mainly through SMAD2/3 with SMAD4, plus SMAD-independent routes.
• ·Early on it enforces growth arrest by inducing p15/p21 and repressing MYC.
• ·Tumours disable the arrest arm (often SMAD4 loss) while keeping pro-invasive, immunosuppressive outputs.
• ·Drug development targets the late, microenvironmental phase, often with immunotherapy.